WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoINTRODUCTION
Ver el documentoGLOSSARY
Abrir esta carpeta y ver su contenido1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
Ver el documento2. THE PROTOCOL
Abrir esta carpeta y ver su contenido3. PROTECTION OF TRIAL SUBJECTS
Abrir esta carpeta y ver su contenido4. RESPONSIBILITIES OF THE INVESTIGATOR
Abrir esta carpeta y ver su contenido5. RESPONSIBILITIES OF THE SPONSOR
Abrir esta carpeta y ver su contenido6. RESPONSIBILITIES OF THE MONITOR
Abrir esta carpeta y ver su contenido7. MONITORING OF SAFETY
Abrir esta carpeta y ver su contenido8. RECORD KEEPING AND HANDLING OF DATA
Abrir esta carpeta y ver su contenido9. STATISTICS AND CALCULATIONS
Abrir esta carpeta y ver su contenido10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Abrir esta carpeta y ver su contenido11. ROLE OF THE DRUG REGULATORY AUTHORITY
Ver el documento12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
Ver el documento13. CONSIDERATIONS FOR MULTICENTRE TRIALS
Ver el documentoREFERENCES
Ver el documentoAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
Ver el documentoAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

2. THE PROTOCOL

The clinical trial should be carried out in accordance with a written protocol agreed upon and signed by the investigator and the sponsor. Any change(s) subsequently required must be similarly agreed on and signed by the investigator and sponsor and appended to the protocol as amendments.

The protocol, appendices and any other relevant documentation should state the aim of the trial and the procedures to be used; the reasons for proposing that it should be undertaken on humans; the nature and degree of any known risks; the groups from which it is proposed that trial subjects be selected and the means for ensuring that they are adequately informed before they give their consent. Other important items to be included in a clinical trial protocol are listed in Appendix 2.

The protocol, appendices and other relevant documentation should be reviewed from a scientific and ethical standpoint by one or more (if required by local laws and regulations), review bodies (e.g. institutional review board, peer review committee, ethics committee, drug regulatory authority), constituted appropriately for this purpose and independent of the investigator(s) and sponsor.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013